Do you want to read an article? Please log in or register.
Triple therapy versus single and dual long-acting bronchodilator therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis
COPD
RECOMMENDED
Related content
RECOMMENDED
COPD
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
Cochrane Database Syst Rev.
Oba Y, Keeney E, Ghatehorde N, Dias S
doi: 10.1002/14651858.
RECOMMENDED
COPD
Triple Therapy versus Dual or Monotherapy with Long-acting Bronchodilators for COPD: A Systematic Review and Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Am Thorac Soc.
Mammen MJ, Lloyd DR, Kumar S, Ahmed AS, Pai V, Kunadharaju R, Gupta S, Nici L, Aaron SD, Alexander PE
doi: 10.1513/AnnalsATS.202001-023OC.
COMMENTED
COPD
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Lancet Respir Med.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C
doi: 10.1016/S2213-2600
Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery
Mol Clin Oncol.
Makino T, Otsuka H, Hata Y, Koezuka S, Azuma Y, Isobe K, Sugino K, Ebihara S, Homma S, Iyoda A
doi: 10.3892/mco.2018.1595.
COPD
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
Lancet.
Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J
doi: 10.1016/
COPD
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
Lancet.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D
doi: 10.1016/S0140-6736
COMMENTED
COPD
Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS
Ann Am Thorac Soc.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, Barr RG, Krishnan JA, Lazarus SC, Cooper CB, Paine R 3rd, Peters SP, Hansel NN, Martinez FJ, Drummond MB, Current and former investigators of the SPIROMICS sites and reading centers
doi: 10.1513/AnnalsATS.201804-283OC.
RECOMMENDED
COPD
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD
doi: 10.1186/s12931-019-1213-9.
RECOMMENDED
COPD
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
Lancet Respir Med.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D
doi: 10.1016/S2213-2600(19)30190-0.